Notice2022-16811
Foreign-Trade Zone (FTZ) 27-Boston, Massachusetts; Notification of Proposed Production Activity, Wyeth Pharmaceuticals, LLC, (COVID-19 Vaccine), Andover, Massachusetts
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 5, 2022
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 150 (Friday, August 5, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 150 (Friday, August 5, 2022)]
[Notices]
[Page 47962]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-16811]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-32-2022]
Foreign-Trade Zone (FTZ) 27--Boston, Massachusetts; Notification
of Proposed Production Activity, Wyeth Pharmaceuticals, LLC, (COVID-19
Vaccine), Andover, Massachusetts
Wyeth Pharmaceuticals, LLC (Wyeth) submitted a notification of
proposed production activity to the FTZ Board (the Board) for its
facility in Andover, Massachusetts within Subzone 27R. The notification
conforming to the requirements of the Board's regulations (15 CFR
400.22) was received on July 27, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status materials/components and
specific finished product described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product and materials/components would be added to the production
authority that the Board previously approved for the operation, as
reflected on the Board's website.
The proposed finished product is COVID-19 vaccine (duty-free).
The proposed foreign-status materials and components include mRNA
drug substance, PF-07311356 ALC-0315 Lipid, 2-[(Polyethylene Glycol)-
2000]-N,N-Ditetradecylacetamide (PEG Lipid ALC-0159), and 1,2-
Distearoyl-sn-glycero-3-phosphocoline (DSPC) (duty rate ranges from
3.7% to 6.5%). The request indicates that certain materials/components
are subject to duties under Section 301 of the Trade Act of 1974
(Section 301), depending on the country of origin. The applicable
Section 301 decisions require subject merchandise to be admitted to
FTZs in privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#4026343a0034322124256e272f36"><span class="__cf_email__" data-cfemail="99ffede3d9edebf8fdfcb7fef6ef">[email protected]</span></a>. The closing period for their receipt is September 14,
2022.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#33775a525d561d755a5d4556417347415257561d545c45"><span class="__cf_email__" data-cfemail="602409010e054e26090e1605122014120104054e070f16">[email protected]</span></a>.
Dated: August 1, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-16811 Filed 8-4-22; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 5, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.